GOSS
Gossamer Bio, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
0.16
▼ 0.00 (1.33%)
MARKET · —
Price
Open
0.15
Prev close
0.16
Day high
0.17
Day low
0.15
Volume
129.41M
Market cap
$75.62M
P/E (TTM)
—
52W range
0.11 – 3.87
Trailing performance
Returnvs SPY
1W
+0.65%
+2.0%
1M
+8.39%
+4.7%
3M
-22.89%
-26.0%
6M
-92.72%
-103.8%
YTD
-95.00%
-107.3%
1Y
-92.05%
-112.0%
3Y
-85.65%
-159.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$75.62M
Enterprise value$58.67M
Revenue (TTM)$53.29M
Gross profit$53.29M
EBITDA$-158.60M
Net income$-125.22M
EPS (TTM)$-0.65
Free cash flow$-29.76M
Total cash$57.03M
Total debt$40.07M
Book value / share$-0.19
Shares outstanding488.85M
Float300.97M
Short % of float19.71%
Dividend yield—
Beta (5Y)2.01
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.85
PEG ratio—
Price / sales—
Price / book—
EV / revenue1.10
EV / EBITDA-0.37
Gross margin100.00%
Operating margin-282.25%
Profit margin-235.00%
Return on equity—
Return on assets-62.39%
Debt / equity—
Current ratio0.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $48.47M | $114.70M | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$170.37M | -$56.53M | -$179.82M | -$229.38M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$170.37M | -$56.53M | -$179.82M | -$229.38M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.12 | -0.10 | +18.2% |
| Mar 2026 | -0.17 | -0.20 | -17.3% |
| Dec 2025 | -0.20 | -0.21 | -7.3% |
| Sep 2025 | -0.20 | -0.21 | -6.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.05 | 6 | $10.81M | -18.7% |
| Next quarter | -0.06 | 6 | $3.00M | -78.3% |
| Current year | -0.18 | 2 | $38.43M | -20.7% |
| Next year | -0.18 | 6 | $25.21M | -34.4% |
Analyst targets & ownership
Mean target$1.66
High target$4.00
Low target$0.28
Implied upside965.64%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 2
Hold3
Sell / Strong sell0 / 1
Held by insiders1.52%
Held by institutions86.98%
Institutions holding199
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
7.43M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jan 2, 26 | HASNAIN FAHEEM Chief Executive Officer |
STOCK | 280.00K | $0 | Direct |
| Jan 2, 26 | GIRAUDO BRYAN M. Chief Operating Officer |
STOCK | 115.75K | $0 | Direct |
| Jan 2, 26 | PETERSON CARYN Officer |
STOCK | 84.50K | $0 | Direct |
| Jan 2, 26 | ARANDA RICHARD Officer |
STOCK | 93.75K | $0 | Direct |
| Jan 2, 26 | CHRISTIAN WAAGE Officer |
STOCK | 84.50K | $0 | Direct |
| Jan 2, 26 | SMITH ROBERT PAUL JR Officer |
STOCK | 93.75K | $0 | Direct |
| Oct 1, 25 | HASNAIN FAHEEM Chief Executive Officer |
STOCK | 437.50K | $0 | Direct |
| Oct 1, 25 | GIRAUDO BRYAN M. Chief Operating Officer |
STOCK | 181.25K | $0 | Direct |
| Oct 1, 25 | PETERSON CARYN Officer |
STOCK | 125.00K | $0 | Direct |
| Oct 1, 25 | ARANDA RICHARD Officer |
STOCK | 162.50K | $0 | Direct |
| Oct 1, 25 | CHRISTIAN WAAGE Officer |
STOCK | 125.00K | $0 | Direct |
| Oct 1, 25 | SMITH ROBERT PAUL JR Officer |
STOCK | 162.50K | $0 | Direct |
| Aug 19, 25 | MILLIGAN SANDRA Director |
BUY | 26.05K | $50.02K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARANDA RICHARD |
Officer | 465.64K | Stock Award(Grant) |
CHRISTIAN WAAGE |
Officer | 882.17K | Stock Award(Grant) |
GIRAUDO BRYAN M. |
Chief Operating Officer | 869.75K | Stock Award(Grant) |
HASNAIN FAHEEM |
Chief Executive Officer | 6.25M | Stock Award(Grant) |
MILLIGAN SANDRA |
Director | 58.05K | Purchase |
PETERSON CARYN |
Officer | 259.33K | Stock Award(Grant) |
SMITH ROBERT PAUL JR |
Officer | 285.90K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
0.16
-3.66% from price
SMA 20
0.17
-10.46% from price
SMA 50
0.17
-7.44% from price
SMA 100
0.24
-34.80% from price
SMA 200
1.22
-87.34% from price
EMA 12
0.16
-3.45% from price
EMA 26
0.17
-6.83% from price
EMA 50
0.20
-21.05% from price
RSI (14)
44.5
Neutral
MACD (12,26,9)
-0.01
Hist -0.00
ATR (14)
0.01
8.85% of price
Realised vol 30D
161.3%
Annualised
Bollinger upper
0.21
20, 2σ
Bollinger lower
0.14
20, 2σ
50 / 200 cross
Death
0.17 vs 1.22
Trend bias
Below 200
-87.34%
Risk profile
Beta vs SPY
2.20
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
161.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-96.4%
Peak to trough
Max drawdown 5Y
-99.1%
Peak to trough
ATR 14
0.01
8.85% of price
Beta (reported)
2.01
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.24
Put-heavy session
Put / call open interest
0.12
Positioning, not flow
Max pain
0.50
+223.2% from spot
ATM implied vol
425.0%
Nearest strike to spot
Skew (10% OTM)
-150.0%
Calls bid over puts
Call volume
33
Contracts, this expiry
Put volume
41
Contracts, this expiry
Heaviest call OI
0.50
108 contracts
Heaviest put OI
0.50
11 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · 23h ago
BC-Most Active Stocks
Associated Press · 1d ago
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval
InvestorsHub · 1d ago
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell
MT Newswires · 1d ago
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Business Wire · 1d ago
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib
Simply Wall St. · 6d ago
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 9d ago
Gossamer Bio: Q2 Earnings Snapshot
Associated Press · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.